FREE MEMBERSHIP Includes » ABL Advisor eNews + iData Blasts | JOIN NOW ABLAdvisor Gray ABLAdvisor Blue
 
Skip Navigation LinksHome / Press Releases / Read Press Release

Print

Oxford Finance Inks $25MM Credit Facility With Enable Injections

September 10, 2020, 09:10 AM
Filed Under: Manufacturing


Enable Injections, Inc., a company developing and manufacturing the enFuse® platform of investigational wearable infusion devices, announced it has completed a credit facility for $25 million from Oxford Finance LLC ("Oxford"), a specialty finance firm that provides senior debt to life sciences and healthcare services companies worldwide. The funds will support the scaling of high-volume manufacturing and achievement of major inflection points as Enable approaches commercialization.

Enable Injections is developing a novel technology to allow patients a safe, convenient, and cost-effective way to deliver their therapies outside of a clinical facility. Designed for ease-of-use, Enable Injections' enFuse® has the potential to allow patients to give themselves their medicine at the time and place of their choosing, which aims to free up healthcare provider resources, minimize exposure to in-home or in-clinic administration by a healthcare provider, and reduce healthcare costs traditionally assigned to biologic therapies. Enable Injections' enFuse® on-body drug delivery platform is designed for subcutaneous delivery of large volumes up to 50mL.

"Enable Injections has engineered an innovative injection platform that provides an opportunity to improve the administration experience for patients and reduce the costs of administration for payors," said Christopher A. Herr, Senior Managing Director at Oxford Finance. "Oxford is pleased to provide the funds to Enable to support further development and commercial preparation initiatives for their momentous infusion devices."

"We are delighted to partner with Oxford Finance in this non-dilutive financing that allows financial flexibility, strengthens our cash position, and enables us to achieve major inflection points that will lead to our commercialization goals on terms that maximize long-term shareholder value," said Tim Flaherty, Executive Vice President and Chief Financial Officer, Enable Injections. "We appreciate Oxford Finance's confidence in the enFuse® technology platform, which has the potential to provide patients and their caregivers an alternative delivery method for subcutaneous administration of parenteral therapies outside of a clinical setting."

Armentum Partners served as financial advisor to Enable Injections in connection with this financing.







Comments From Our Members

You must be an ABL Advisor member to post comments. Login or Join Now.